Drug Information Analysis Service

Corsini RJ , ed. Encyclopedia of psychology. New York: John Wiley & Sons, 1984: 332–4.

Puzynski S. Klosiewicz L. Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders. Psychopharmacol Bull 1984; 20: 151–9.

Rimmer EM Richens A. An update on sodium valproate. Pharmacotherapy 1985; 5: 171–81.

McElroy SL Keck PE Jr Pope HG Jr Hudson JI. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 1988; 8: 275–9.

Emrich HM Von Zerssen D. Kissling W. Mollwer JH Windorfer A. Effect of sodium valproate on mania. Arch Psychiatr Nervenkrankh 1980; 229: 1–16.

Von Zerssen D. Cording C. The measurement of change in endogenous affective disorders. Arch Psychiatr Nervenkrankh 1978; 226: 95–112.

Brennan M. Sandyj R. Borsook D. Use of sodium valproate in the management of affective disorders: basic and clinical aspects. In: Emrich HM Okuma T. Muller AA , eds. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984: 56–65.

McElroy SL Keck PE Jr Pope HG Jr Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16–24.

McElroy SL Keck PE Jr Pope HG Jr Hudson JI. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50 (suppl): 23–9.

Glauber H. Wallace P. Griver K. Brechtel G. Adverse effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108: 663–8.

Leaf A. Weber PC Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 318: 549–57.

Kamada T. Yamashita T. Baba Y. Dietary sardine oil increases erythrocyte membrane fluidity in diabetic patients. Diabetes 1986; 35: 604–11.

Friday KE Childs M. Tsunehara C. Fujimoto WY Bierman EL Ensinck JW Omega-3 fatty acid supplementation has discordant effects on plasma glucose and lipoproteins in type II diabetes (abstract). Diabetes 1987; 36: 12A.

Popp-Snijders C. Schouten JA Heine RJ Van Der Meer J. Van Der Veen EA Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes. Diabetes Res 1987; 4: 141–7.

Kasim SE Stern B. Khilnani S. McLin P. Baciorowski S. Jen KLC Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients. J Clin Endocrinol Metab 1986; 67: 1–5.

Schetman G. Kaul S. Kissebah AH Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988; 37: 1567–73.

Kastrup EK Olin BR Connell SI Hebel SK , eds. Drug facts and comparisons. St. Louis: JB Lippincott, 1989: 153.

Kimble MK Rotbatt MD Diabetes mellitus. In: Young LY Koda-Kimble MA , eds. Applied therapeutics: The clinical use of drugs. 4th ed. Vancouver, WA: Applied Therapeutics, Inc. 1988: 1669–70.

Parving HH Hommel E. Smidt UM Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297: 1086–91.

Andersen AR Rennke HG Brenner BM Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000.

Hostetter TH Rennke HG Brenner BM The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375–80.

Parving HH Viberti GC Keen H. Christiansen JS Lassen NA Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983; 32: 943–9.

Bohrer MP Deen WM Robertson CR Brenner BM Mechanisms of angiotensin II induced proteinuria in the rat. Am J Physiol 1977; 233: F13–21.

Marre M. Chatellier G. Leblanc H. Guyene TT Menard J. Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092–5.

Parving HH Andersen AR Smidt UM Svendsen PA Effect of antihypertensive treatment on diabetic nephropathy in insulin-dependent diabetic patients. In: Friedman EA L'Esperance FA , eds. Diabetic renal-retinal syndrome. New York: Grune and Stratton 1986: 183–90.

Hommel E. Parving HH Mathiesen E. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293: 467–70.

Bjorck S. Nyberg G. Mulec H. Granerus G. Herlitz H. Mattias A. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471–4.

Taguma Y. Kitamoto Y. Futaki G. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–20.

Valvo E. Bedogna V. Casagrande P. Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med 1988; 85: 344–8.

Struthers AD. The choice of antihypertensive therapy in the diabetic patient. Postgrad Med J 1985; 61: 563–9.

Bengtsson C. Blohme G. Lapidus L. Do antihypertensive drugs precipitate diabetes? Br Med J 1984; 289: 1495–7.